Cartesian Therapeutics (RNAC) Operating Expenses (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Operating Expenses for 12 consecutive years, with $26.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 15.61% year-over-year to $26.6 million; the TTM figure through Mar 2026 stood at $149.8 million (up 72.95% YoY), while the FY2025 annual figure was $146.2 million, up 76.55% from the prior year.
• Operating Expenses eased to $26.6 million in Q1 2026 per RNAC's latest filing, from $79.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $79.6 million in Q4 2025 and bottomed at $18.0 million in Q3 2024.
• Historically, Operating Expenses has averaged $27.3 million across 5 years, with a median of $23.2 million in 2022.
• Annual changes were most pronounced in 2024 — Operating Expenses plunged 41.76% — and 2025, when it surged 206.43%.
• Cartesian Therapeutics' Operating Expenses stood at $25.3 million in 2022, then surged by 76.34% to $44.6 million in 2023, then slumped by 41.76% to $26.0 million in 2024, then soared by 206.43% to $79.6 million in 2025, then plunged by 66.61% to $26.6 million in 2026.
• Business Quant data shows RNAC's Operating Expenses at $26.6 million in Q1 2026, $79.6 million in Q4 2025, and $21.5 million in Q3 2025.